title: Prediction of the Carcinogenic Potential of Human Pharmaceuticals Using Repeated Dose Toxicity Data and Their Pharmacological Properties.
abstract: In an exercise designed to reduce animal use, we analyzed the results of rat subchronic toxicity studies from 289 pharmaceutical compounds with the aim to predict the tumor outcome of carcinogenicity studies in this species. The results were obtained from the assessment reports available at the Medicines Evaluation Board of the Netherlands for 289 pharmaceutical compounds that had been shown to be non-genotoxic. One hundred forty-three of the 239 compounds not inducing putative preneoplastic lesions in the subchronic study did not induce tumors in the carcinogenicity study [true negatives (TNs)], whereas 96 compounds were categorized as false negatives (FNs) because tumors were observed in the carcinogenicity study. Of the remaining 50 compounds, 31 showed preneoplastic lesions in the subchronic study and tumors in the carcinogenicity study [true positives (TPs)], and 19 only showed preneoplastic lesions in subchronic studies but no tumors in the carcinogenicity study [false positives (FPs)]. In addition, we then re-assessed the prediction of the tumor outcome by integrating the pharmacological properties of these compounds. These pharmacological properties were evaluated with respect to the presence or absence of a direct or indirect proliferative action. We found support for the absence of cellular proliferation for 204 compounds (TN). For 67 compounds, the presence of cellular hyperplasia as evidence for proliferative action could be found (TP). Therefore, this approach resulted in an ability to predict non-carcinogens at a success rate of 92% and the ability to detect carcinogens at 98%. The combined evaluation of pharmacological and histopathological endpoints eventually led to only 18 unknown outcomes (17 categorized as FN and 1 as FP), thereby enhancing both the negative and positive predictivity of an evaluation based upon histopathological evaluation only. The data show the added value of a consideration of the pharmacological properties of compounds in relation to potential class effects, both in the negative and positive direction. A high negative and a high positive predictivity will both result in waiving the need for conducting 2-year rat carcinogenicity studies, if this is accepted by Regulatory Authorities, which will save large numbers of animals and reduce drug development costs and time.
authors: Medicines Evaluation Board, Utrecht, Netherlands; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden, Netherlands.
authors: Jan Willem
authors: JW
authors: van der Laan
authors: Medicines Evaluation Board , Utrecht , Netherlands.
authors: Wenny H W
authors: WH
authors: Buitenhuis
authors: Veterinary Faculty, IRAS , Utrecht , Netherlands.
authors: Laura
authors: L
authors: Wagenaar
authors: Division of Toxicology, Wageningen University and Research Centre , Wageningen , Netherlands.
authors: Ans E M F
authors: AE
authors: Soffers
authors: TNO Innovation for Life , Zeist , Netherlands.
authors: Eugene P
authors: EP
authors: van Someren
authors: TNO Innovation for Life , Zeist , Netherlands.
authors: Cyrille A M
authors: CA
authors: Krul
authors: Division of Toxicology, Wageningen University and Research Centre, Wageningen, Netherlands; TNO Innovation for Life, Zeist, Netherlands.
authors: Ruud A
authors: RA
authors: Woutersen
keywords: carcinogenicity; histopathology; human pharmaceuticals; pharmacology; predictivity